CHRM3 and glioma: Cholinergic receptor genes exhibited varying levels of expression across malignant cells within DMG tumors (Figure S9A), reflecting intratumoral heterogeneity—a phenomenon well-described in this disease11 and in gliomas in general.46–48 Pseudo-bulk expression in malignant cells revealed that the muscarinic receptor CHRM3 was highly expressed across all glioma subtypes, as well as in ependymoma and medulloblastoma (Figure S9B).